Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11904974 | 0.91 | GSK3B (0.60) | GSK3BCYP2D6CYP1A2CYP3A4CSNK1A1 | |
| SCHEMBL9944015 | 0.90 | GSK3B (0.59) | GSK3BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL9943976 | 0.90 | GSK3B (0.63) | GSK3BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL11905660 | 0.85 | GSK3B (0.62) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL11904961 | 0.84 | GSK3B (0.62) | GSK3BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL9944026 | 0.83 | GSK3B (0.60) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL11905207 | 0.80 | GSK3B (0.56) | GSK3BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL11905164 | 0.79 | GSK3B (0.55) | GSK3BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL11904985 | 0.79 | GSK3B (0.58) | GSK3BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL11905302 | 0.79 | GSK3B (0.61) | GSK3BCYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | claimed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | claimed |
| EP-2464632-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | claimed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | GSK3B 256/4885CYP2D6 3752/4885CYP1A2 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.